{"id":5792,"date":"2026-02-10T09:00:00","date_gmt":"2026-02-10T14:00:00","guid":{"rendered":"https:\/\/www.bvimedical.com\/us\/?p=5792"},"modified":"2026-02-06T11:41:24","modified_gmt":"2026-02-06T16:41:24","slug":"bvi-completes-first-u-s-implantations-of-fda-approved-finevision-hp-trifocal-iol","status":"publish","type":"post","link":"https:\/\/www.bvimedical.com\/us\/bvi-completes-first-u-s-implantations-of-fda-approved-finevision-hp-trifocal-iol\/","title":{"rendered":"BVI Completes First U.S. Implantations of FDA-Approved FINEVISION\u00ae HP Trifocal IOL"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li>BVI announced the first successful U.S. implantations of its FDA-approved FINEVISION\u00ae HP trifocal IOL, marking the transition from regulatory clearance to real-world surgical use.<\/li>\n\n\n\n<li>Five leading cataract and refractive surgeons performed the initial procedures, advancing BVI\u2019s disciplined, surgeon-led rollout of a category-defining trifocal platform with more than 15 years of global clinical use and proven patient outcomes.<\/li>\n<\/ul>\n\n\n\n<p>WALTHAM, Mass., February 10, 2026 \u2014 BVI, a global leader in ophthalmic device innovation, announced the first successful U.S. implantations of its FDA-approved FINEVISION HP hydrophobic trifocal intraocular lens (IOL), marking the long-anticipated arrival of one of the most established trifocal platforms in global cataract surgery and a major milestone following the product\u2019s U.S. regulatory clearance in October 2025.<\/p>\n\n\n\n<p>Five leading cataract and refractive surgeons, all members of BVI\u2019s U.S. Surgical Leadership Council, performed the initial procedures at multiple surgical centers across the country:<\/p>\n\n\n\n<div class=\"wp-block-group is-vertical is-layout-flex wp-container-core-group-is-layout-8cf370e7 wp-block-group-is-layout-flex\">\n<ul class=\"wp-block-list\">\n<li>George O. Waring IV, MD, Ladson, SC<\/li>\n\n\n\n<li>Nathan M. Radcliffe, MD, Bronx, NY<\/li>\n\n\n\n<li>Nicole Fram, MD, Beverly Hills, CA<\/li>\n\n\n\n<li>Robert J. Weinstock, MD, Largo, FL<\/li>\n\n\n\n<li>Vance Thompson, MD, Sioux Falls, SD &nbsp;<\/li>\n<\/ul>\n<\/div>\n\n\n\n<p>These first clinical cases represent the transition of FINEVISION HP from regulatory approval to real-world U.S. surgical practice, advancing BVI\u2019s strategy to expand its premium refractive portfolio in the world\u2019s largest ophthalmic market.<\/p>\n\n\n\n<p>FINEVISION HP received FDA approval in October 2025, bringing the original, clinically proven trifocal IOL to the U.S. market. Developed through the collaboration of BVI R&amp;D Director Christophe Pagnoulle and ophthalmologist Damien Gatinel, MD, PhD, FINEVISION HP builds on more than 15 years of global clinical and real-world experience, with widespread use outside the United States.<\/p>\n\n\n\n<p>\u201cThe recent entry of BVI into the U.S. presbyopia-correcting IOL market with FINEVISION HP is well timed and very exciting. As a global leader in surgical eye care, BVI\u2019s vision and passion for excellence have the potential to meaningfully advance presbyopia correction for surgeons and patients alike.\u201d said George O. Waring IV, MD one of the first U.S. surgeons to implant the lens.<\/p>\n\n\n\n<p>The third-generation FINEVISION HP incorporates BVI\u2019s proprietary POD\u2122 platform and CoPODize\u2122 technology, an advanced diffractive optical design refined over time while remaining true to its original optical principles to balance and harmonize light distribution across distance, intermediate, and near focal points while minimizing visual disturbances. Its unique double C-loop haptic design \u2014 provides four points of in-bag contact and a 120\u00b0 contact angle, compared with conventional C-loop configurations.<\/p>\n\n\n\n<p>U.S. clinical evaluation and global evidence have demonstrated strong contrast sensitivity, stable visual performance across all lighting conditions, including enhanced near vision in dim light, and a smooth, continuous range of vision from far to near.<\/p>\n\n\n\n<p>&#8220;As a third-generation design, FINEVISION\u00ae HP reflects the latest advances in presbyopia-correcting IOL technology, incorporating an optical platform refined over time to meet the evolving expectations of today\u2019s premium cataract surgeons,\u201d said Andy Chang, Chief Commercial Officer of BVI. \u201cThis milestone marks the moment when a category-defining trifocal platform, backed by more than 15 years of global clinical use and demonstrated outcomes in delivering consistent, balanced, high-quality vision for patients, officially enters U.S. surgical practice. We are deeply grateful to the pioneering surgeons who performed these first U.S. implantations, as well as to the BVI teams whose expertise and commitment have supported this disciplined, surgeon-led rollout. Together, we are proud to expand access to this proven technology across the United States throughout 2026.\u201d<\/p>\n\n\n\n<p>Building on its FDA approval and global foundation, BVI is methodically rolling out FINEVISION HP across select U.S. centers, prioritizing surgeon training, phased availability, and real-world performance validation. Broader access is expected to expand throughout the country during 2026 as manufacturing capacity increases and surgeon onboarding progresses.<\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong>***<\/strong><\/p>\n\n\n\n<p><strong>About BVI<\/strong><\/p>\n\n\n\n<p>BVI\u00ae is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving patients\u2019 vision. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors.<\/p>\n\n\n\n<p>To learn more about BVI and its mission to advance the future of vision, visit <a href=\"https:\/\/www.bvimedical.com\">https:\/\/www.bvimedical.com<\/a><\/p>\n\n\n\n<div class=\"wp-block-group is-vertical is-layout-flex wp-container-core-group-is-layout-8cf370e7 wp-block-group-is-layout-flex\">\n<p><strong>Press Contact<\/strong><\/p>\n\n\n\n<p>David Chavez<\/p>\n\n\n\n<p>Global Communications Lead<\/p>\n\n\n\n<p><a href=\"mailto:dchavez@bvimedical.com\">dchavez@bvimedical.com<\/a><\/p>\n\n\n\n<p>+1 (857) 869 8706<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., February 10, 2026 \u2014 BVI, a global leader in ophthalmic device innovation, announced the first successful U.S. implantations of its FDA-approved FINEVISION HP hydrophobic trifocal intraocular lens (IOL), marking the long-anticipated arrival of one of the most established trifocal platforms in global cataract surgery and a major milestone following the product\u2019s U.S. regulatory [&hellip;]<\/p>\n","protected":false},"author":452,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[17],"tags":[],"class_list":["post-5792","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/posts\/5792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/users\/452"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/comments?post=5792"}],"version-history":[{"count":0,"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/posts\/5792\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/media?parent=5792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/categories?post=5792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/tags?post=5792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}